Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
复制标题
DOI：
10.1007/s100720200066
复制
发表时间：
2002-09-01
影响因子：
3.3
通讯作者：
Quattrone, A
中科院分区：
文献类型：
--
作者：
Arabia, G;Zappia, M;Quattrone, A
我们对164例散发性帕金森病（PD）患者进行了药代动力学研究，以探讨体重与左旋多巴药代动力学之间的关系。患者接受250 mg左旋多巴口服急性左旋多巴试验，并进一步评估药代动力学变量。血浆左旋多巴曲线下面积（AUC-1）和体重呈显著负相关。女性比男性明显更轻，运动障碍更严重，AUC-1值更大。我们的数据表明，在长期治疗期间，较轻的PD患者，特别是女性，可能会接受每公斤体重更大的左旋多巴累积剂量。这可以解释在疾病过程中观察到的左旋多巴诱导的峰值剂量运动障碍的发展的性别差异。
We conducted a pharmacokinetic study in 164 patients with sporadic Parkinson's disease (PD) to address the relationship between body weight and levodopa pharmacokinetics. Patients underwent an oral acute levodopa test with 250 mg levodopa and pharmacokinetic variables were further assessed. Plasmatic levodopa area under the curve (AUC-1) and body weight were significantly and inversely correlated. Women were significantly lighter and more dyskinetic than men, and had greater AUC-1 values. Our data suggest that during long-term treatment, lighter PD patients, especially women, may receive a greater cumulative dosage of levodopa per kilogram of body weight. This could explain gender differences for the development of levodopa-induced peak-dose dyskinesias observed during the course of the disease.